BIOQ Stock Overview
Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bioqual, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.10 |
| 52 Week High | US$80.00 |
| 52 Week Low | US$66.10 |
| Beta | -0.25 |
| 1 Month Change | -2.07% |
| 3 Month Change | -2.07% |
| 1 Year Change | n/a |
| 3 Year Change | -32.03% |
| 5 Year Change | 42.15% |
| Change since IPO | 21,932.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOQ | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -2.1% | -2.1% | -2.4% |
| 1Y | n/a | -5.5% | 23.4% |
Return vs Industry: Insufficient data to determine how BIOQ performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how BIOQ performed against the US Market.
Price Volatility
| BIOQ volatility | |
|---|---|
| BIOQ Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 9.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOQ's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BIOQ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Mark Lewis | www.bioqual.com |
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.
Bioqual, Inc. Fundamentals Summary
| BIOQ fundamental statistics | |
|---|---|
| Market cap | US$59.12m |
| Earnings (TTM) | -US$1.09m |
| Revenue (TTM) | US$54.78m |
1.1x
P/S Ratio-54.2x
P/E RatioIs BIOQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOQ income statement (TTM) | |
|---|---|
| Revenue | US$54.78m |
| Cost of Revenue | US$56.89m |
| Gross Profit | -US$2.11m |
| Other Expenses | -US$1.02m |
| Earnings | -US$1.09m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | -3.85% |
| Net Profit Margin | -1.99% |
| Debt/Equity Ratio | 0% |
How did BIOQ perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield-41%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:21 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bioqual, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|